Royal Bank Of Canada Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its target price boosted by stock analysts at Royal Bank Of Canada from $217.00 to $233.00 in a report released on Monday, Marketbeat Ratings reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 23.29% from the company’s current price.

Other equities analysts have also issued reports about the stock. HSBC reissued a “reduce” rating and issued a $143.00 target price (down from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Guggenheim lifted their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research note on Monday. UBS Group assumed coverage on shares of Biogen in a research report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective for the company. Jefferies Financial Group raised their target price on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a report on Friday, November 28th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a research note on Monday. Thirteen analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $207.81.

Biogen Price Performance

Biogen stock opened at $188.99 on Monday. The firm has a market cap of $27.74 billion, a PE ratio of 21.45, a price-to-earnings-growth ratio of 1.55 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The stock’s fifty day moving average price is $177.44 and its two-hundred day moving average price is $157.89. Biogen has a one year low of $110.04 and a one year high of $202.41.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the firm posted $3.44 EPS. Biogen’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Several large investors have recently bought and sold shares of the company. Rothschild Investment LLC boosted its stake in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares in the last quarter. Advisory Services Network LLC raised its holdings in Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 68 shares during the last quarter. CVA Family Office LLC boosted its position in Biogen by 18.1% during the 3rd quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after buying an additional 71 shares during the period. Davis Investment Partners LLC boosted its position in Biogen by 1.7% during the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after buying an additional 71 shares during the period. Finally, Optas LLC grew its holdings in Biogen by 4.5% during the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 73 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.